VIOLIN Logo
VO Banner
Search: for Help
Vaxjo Home
Introduction
Statistics
News and Updates
Vaxjo Query
Selected Adjuvants
adamantylamide dipeptide vaccine adjuvant
aluminum hydroxide vaccine adjuvant
alhydrogel vaccine adjuvant
Data Submission
Data Exchange
Data Download
Documentation
FAQs
Disclaimer
Contact Us
UMMS Logo

CCL21 and IL1β

Vaxjo ID 283       
Vaccine Adjuvant Name CCL21 and IL1β       
Adjuvant VO ID VO_0005771
Description This is a recombinant fusion protein of human CCL21 (a chemokine) and a non-inflammatory epitope of IL1β (VQGEESNDK). It was codon-optimized and produced in transgenic tobacco (Nicotiana tabacum). It aims to function as a tumor immunotherapy adjuvant, particularly for breast cancer (MCF7 cell line)       
Stage of Development Research       
Host Species for Testing Mouse       
Components A codon-optimized ccl21/IL1β gene was designed and synthesized from human genes.       
Structure Fusion of CCL21 and IL1β epitope connected by EAAAK linker. 3D structure modeled using Modeller 9.24. Interacts with the CCR7 receptor on T-cells       
Appearance Protein purified from transgenic plant leaves; visualized by SDS-PAGE and western blotting.       
Preparation Synthesized using codon-optimized gene introduced into Agrobacterium tumefaciens, then transferred to tobacco leaves. Expressed under the pBI121 binary vector. Purified using Ni-IDA resin via His-tagSynthesized using codon-optimized gene introduced into Agrobacterium tumefaciens, then transferred to tobacco leaves. Expressed under the pBI121 binary vector. Purified using Ni-IDA resin via His-tag       
Dosage In vitro testing used concentrations of 2.5–10 μg/ml; optimal at 7.5 μg/ml for anti-cancer activity in MCF7 cells       
Function The results demonstrated a decrease in survival rate and metastasization of cancer cells in the presence of CCL21/IL1尾, and IC50 of CCL21 on MCF7 cells was less than that of non-recombinant protein.聽       
Safety Predicted to be non-allergenic (AlgPred). Stability index supports protein stability. In vitro assays did not report cytotoxicity beyond targeted cancer cells       
References
Marashi et al., 2022: Marashi H, Beihaghi M, Chaboksavar M, Khaksar S, Tehrani H, Abiri A. In silico analysis and in planta production of recombinant ccl21/IL1β protein and characterization of its in vitro anti-tumor and immunogenic activity. PloS one. 2022; 17(8); e0261101. [PubMed: 36037155].